Bavarian Nordic (OTCMKTS:BVNRY) Issues Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) issued its quarterly earnings results on Wednesday. The company reported $0.01 EPS for the quarter, Zacks reports. The company had revenue of $165.70 million during the quarter. Bavarian Nordic had a return on equity of 11.27% and a net margin of 22.20%.

Bavarian Nordic Stock Down 6.0%

Shares of Bavarian Nordic stock traded down $0.62 on Thursday, reaching $9.68. 1,357 shares of the stock were exchanged, compared to its average volume of 3,525. The business has a 50 day moving average price of $9.85 and a two-hundred day moving average price of $10.08. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of 11.00 and a beta of 1.21. Bavarian Nordic has a twelve month low of $7.94 and a twelve month high of $13.00.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.